ENX ‐101, a GABA A receptor α2,3,5‐selective positive allosteric modulator, displays antiseizure effects in rodent seizure and epilepsy models
Open Access
Abstract
Objective: γ‐Aminobutyric acid type A (GABA A ) receptor positive allosteric modulators (PAMs) that lack α‐subunit selectivity, including benzodiazepines such as diazepam, exhibit antiseizure actions in animal models and in humans. ENX‐101 is a deuterated analog of the ⍺2,3,5‐selective GABA A receptor PAM L‐838,417. The purpose of this study was to characterize the α‐subunit selectivity of ENX‐101 and evaluate its antiseizure potential in preclinical seizure and epilepsy models. Methods: ENX‐101 potentiation of GABA chloride current responses in cells expressing recombinant GABA A receptors were evaluated using an automated patch clamp assay. Antiseizure effects of ENX‐101 were examined in the mouse 6 Hz test at 32 and 44 mA, amygdala kindled rats, and Genetic Absence Epilepsy Rat from Strasbourg (GAERS). Results: ENX‐101 displayed partial PAM activity with respect to diazepam at GABA A receptors containing α2, α3, or α5 subunits but did not enhance GABA responses of GABA A receptors containing α1 subunits. ENX‐101 (30, 100, and 300 mg/kg, i.p.) and diazepam protected most animals in the 6 Hz model at 32 mA but was less effective at 44 mA. In amygdala kindled rats, ENX‐101 (1–100 mg/kg, p.o.) reduced behavioral seizure severity and afterdischarge duration in a dose‐dependent manner. ENX‐101 (0.075–100 mg/kg, p.o.) caused dose‐dependent, persistent (>130 min) inhibition of spontaneous spike‐and‐wave discharges (SWDs) in GAERS, whereas diazepam transiently inhibited discharges. ENX‐101 did not cause motor impairment, as measured by performance in the rotarod assay. Significance: ENX‐101 is an α2,α3,α5‐selective GABA A receptor PAM that has high potency and partial efficacy. The drug is highly effective in rodent seizure and epilepsy models. ENX‐101 is most potent in the GAERS model of absence epilepsy, and active in the 6 Hz model and amygdala kindled rats. These results demonstrate that a partial, subtype‐selective GABA A receptor PAM has activity in translationally validated preclinical epilepsy screening models. Clinical evaluation of ENX‐101 as a treatment for focal and generalized epilepsies is warranted.Keywords
This publication has 50 references indexed in Scilit:
- BAER‐101, a selective potentiator of α2‐ and α3‐containing GABAA receptors, fully suppresses spontaneous cortical spike‐wave discharges in Genetic Absence Epilepsy Rats from Strasbourg (GAERS)Drug Development Research, 2024
- GABAA Receptor Subtypes and the Reinforcing Effects of Benzodiazepines in Remifentanil-Experienced Rhesus MonkeysDrug and Alcohol Dependence, 2020
- Self-administration of benzodiazepine and cocaine combinations by male and female rhesus monkeys in a choice procedure: role of α1 subunit–containing GABAA receptorsPsychopharmacology, 2019
- The immunohistochemical distribution of the GABA A receptor α 1 , α 2 , α 3 , β 2/3 and γ 2 subunits in the human thalamusJournal of Chemical Neuroanatomy, 2017
- Validation of a Preclinical Drug Screening Platform for Pharmacoresistant EpilepsyNeurochemical Research, 2017
- Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L‐838417Biopharmaceutics & Drug Disposition, 2004
- Effect of deuteration of imipramine on its pharmacokinetic properties in the ratBiochemical Pharmacology, 1983
- The anticonvulsant effects of diazepam and phenobarbital in prekindled and kindled seizures in ratsNeuropharmacology, 1981
- Behavioral analysis of the effects of 15 anticonvulsants in the amygdaloid kindled ratPsychopharmacology, 1979
- Modification of seizure activity by electrical stimulation: I. after-discharge thresholdElectroencephalography and Clinical Neurophysiology, 1972